Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05255588Completed

A Stool DNA-based SDC2 Methylation Test for the Early Detection of Colorectal Cancer

Role: lead

NCT04304131Not ApplicableCompleted

Colorectal Cancer Screening Using Stool DNA-based SDC2 Methylation Test

Role: collaborator

NCT03146520Completed

Clinical Validation of Stool DNA-based SDC2 Methylation Test for Colorectal Cancer Detection

Role: lead

All 3 trials loaded